Deep Learning Model Predicts Response to Combination Therapy Prior to Treatment in HCC
April 5th 2024Researchers developed a web server that can help predict therapeutic responses to combination lenvatinib and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma (HCC).
Read More
Study: Patients With SLE, AF Experience Higher In-Hospital Mortality Rate
April 5th 2024Patients with systemic lupus erythematosus (SLE) and atrial fibrillation (AF) exhibited elevated risks of severe cardiac complications, alongside increased in-hospital mortality, costs, and length of stay (LOS).
Read More
CMS finalizes policies to enhance consumer protections, promote competition, and expand access to care for Medicare Advantage (MA) and Medicare Part D; digital therapeutic Rejoyn receives FDA clearance for adults with major depressive disorder (MDD); study reveals minimal symptom reduction from nirmatrelvir–ritonavir (Paxlovid) in high-risk, fully vaccinated patients.
Read More
Jon Levitt Highlights Urgency for Stronger Employer Oversight of PBMs
April 5th 2024Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.
Watch
Small Study Shows Safety, Efficacy of Prophylactic rIX-FP in Previously Untreated Hemophilia B
April 5th 2024Findings from this new study demonstrate the safety and efficacy of rIX-FP among a group of treatment-naive patients often characterized by young age and particular risk for severe bleeding.
Read More
Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis
April 4th 2024Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.
Read More
The newest treatment approved for amyotrophic lateral sclerosis (ALS) will be withdrawn from the market due to negative clinical trial results; former President Trump’s surgeon general is advocating for conservative states to support needle exchanges; new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases.
Read More
Combination Therapies Optimize Hair Regrowth in Pediatric Patients With AA
April 4th 2024Corticosteroids are the most common treatment for pediatric patients with alopecia areata (AA), but promising newer options like JAK inhibitors are emerging. This review highlights the importance of personalized treatment plans and maximizing response through combination therapies.
Read More
Study: 1 in 6 US Patients With COPD Suffers From Cost-Related Medication Nonadherence
April 3rd 2024Medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) is associated with increasing COPD symptoms, hospitalizations, morbidity, mortality, and health care expenditures.
Read More
Antismoking groups sued the US government over the long-awaited menthol cigarette ban; the fill rate for Adderall and Vyvanse dropped more than 10% in 2 years despite soaring demand; the Biden administration has responded to offers from the manufacturers of drugs selected for Medicare pricing negotiations.
Read More
Children Born to Mothers With Stress, Mental Health Conditions During Pregnancy at Higher AD Risk
April 2nd 2024A meta-analysis found significant associations between maternal stress, anxiety, depression, and adverse life events during pregnancy with increased atopic dermatitis (AD) risk in offspring.
Read More